1. Clinical Overview
A sterile, multi-dose ophthalmic solution combining a mydriatic-cycloplegic (Atropine), a broad-spectrum bacteriostatic antibiotic (Chloramphenicol), and a potent corticosteroid (Dexamethasone). It is primarily indicated for the management of severe ocular inflammation and infection where cycloplegia is required to relieve pain and prevent synechiae formation. This combination is a mainstay in treating conditions like severe uveitis, post-operative inflammation, and penetrating ocular injuries with infection risk.
| Onset | Duration | Bioavailability |
|---|---|---|
| Atropine: Mydriasis begins within 30-40 minutes, maximal cycloplegia in 60-90 minutes. Chloramphenicol: Antibacterial action begins immediately upon contact. Dexamethasone: Anti-inflammatory effects typically observed within hours. | Atropine: Mydriasis and cycloplegia can last 7-10 days or longer. Chloramphenicol: Local antibacterial effect is sustained with regular dosing. Dexamethasone: Local anti-inflammatory effect lasts 6-8 hours per instillation. | Primarily local/topical ocular bioavailability. Systemic absorption via nasolacrimal duct is minimal but can occur, especially with atropine. |
2. Mechanism of Action
The combination exerts a triple action: 1) Atropine competitively blocks acetylcholine at muscarinic (M3) receptors of the iris sphincter and ciliary muscle, causing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). This relieves pain from ciliary spasm and prevents formation of posterior synechiae. 2) Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. It is bacteriostatic against a wide range of Gram-positive and Gram-negative bacteria, including H. influenzae and S. aureus. 3) Dexamethasone binds to glucocorticoid receptors, inducing the synthesis of anti-inflammatory proteins (lipocortins) and inhibiting the production of pro-inflammatory mediators (prostaglandins, leukotrienes, cytokines). It suppresses inflammation, capillary dilation, edema, and fibroblast proliferation.
3. Indications & Uses
- Severe anterior uveitis (iritis, iridocyclitis) with infection or high risk thereof
- Post-operative ocular inflammation following intraocular surgery (e.g., cataract, glaucoma) with prophylaxis/treatment of infection
- Penetrating ocular injuries or corneal ulcers with significant inflammation and bacterial infection risk
4. Dosage & Administration
Adult Dosage: 1-2 drops into the affected eye(s) every 4 to 6 hours. In severe conditions, may be used every 1-2 hours initially, tapering as inflammation subsides. Frequency and duration MUST be determined by an ophthalmologist.
Administration: 1. Wash hands. 2. Tilt head back. 3. Gently pull lower eyelid to form a pouch. 4. Instill prescribed drops without touching the dropper tip. 5. Close eyes gently for 1-2 minutes. 6. Apply gentle pressure on the nasolacrimal duct (inner corner of eye) for 1 minute to minimize systemic absorption. 7. Wait at least 5-10 minutes before instilling any other eye drops.
5. Side Effects
Common side effects may include:
- Transient stinging/burning on instillation
- Blurred vision (due to cycloplegia)
- Photophobia (due to mydriasis)
- Pupillary dilation (mydriasis)
- Difficulty with near vision (loss of accommodation)
- Mild conjunctival hyperemia
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Other Anticholinergics (e.g., Ipratropium, Tiotropium, Scopolamine, TCAs) | Additive systemic anticholinergic side effects (dry mouth, urinary retention, tachycardia, confusion). | Moderate |
| Systemic Corticosteroids (e.g., Prednisolone) | Additive systemic steroid effects (hyperglycemia, adrenal suppression, osteoporosis). | Moderate |
| Warfarin and other Coumarin Anticoagulants | Chloramphenicol may inhibit metabolism, increasing anticoagulant effect and risk of bleeding. | Major |
| Phenytoin, Phenobarbital | Chloramphenicol may increase levels of these drugs; these drugs may decrease chloramphenicol levels. | Moderate |
| Sulfonylureas (e.g., Glipizide) | Chloramphenicol may increase hypoglycemic effect. Dexamethasone may increase blood glucose. | Moderate |
| Cholinesterase Inhibitors (e.g., Pilocarpine, Physostigmine) | Direct pharmacological antagonism with Atropine, reducing therapeutic effect of both. | Major |
7. Patient Counselling
- DO wash hands before use.
- DO apply nasolacrimal pressure for 1 minute after instillation.
- DO wait 5-10 minutes before using other eye drops.
- DO keep bottle tip clean and avoid touching it.
- DO report any eye pain, vision changes, or signs of infection immediately.
- DONT drive or operate machinery while on this medication.
- DONT wear contact lenses during treatment unless approved by doctor.
- DONT stop medication abruptly if used for more than 2 weeks; taper as directed.
- DONT share your eye drops with others.
8. Toxicology & Storage
Overdose: Topical: Exacerbation of local side effects (severe blurred vision, intense photophobia, severe eye pain from angle-closure glaucoma). Systemic (from excessive absorption): Atropine - Fever, dry skin, flushing, tachycardia, hypertension, restlessness, confusion, hallucinations, delirium, urinary retention. Chloramphenicol - Nausea, vomiting, gray baby syndrome in neonates (vasomotor collapse, cyanosis, acidosis), bone marrow suppression. Dexamethasone - Cushingoid symptoms, severe hyperglycemia, psychosis.
Storage: Store at controlled room temperature (15-25°C). Protect from light. Keep the bottle tightly closed when not in use. Do not freeze. Keep out of reach and sight of children. Discard the bottle 4 weeks after opening to prevent contamination. Do not use if the solution is discolored or contains particles.